ReviewDiscover nano2026
Role of tannin-rich plant fractions in hepatoprotection: a nanotechnology perspective.
Review in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Liposomal Myricetin Nanoantioxidants Attenuate Methotrexate-Induced Hepatotoxicity by Modulating Oxidative Stress, Inflammation, and Apoptosis in Rats.Antioxidants (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The liver, a vital organ for metabolic and detoxification processes, is often vulnerable to damage from toxins, drugs, and diseases. Tannins, a class of polyphenolic compounds found in various plants, exhibit promising hepatoprotective properties by enhancing liver cell viability and function, mitigating oxidative stress, and promoting anti-apoptotic, anti-inflammatory, and detoxifying effects. These phenolic compounds effectively protect against liver injuries. However, their clinical utility is hampered by poor bioavailability, rapid metabolism, and stability issues. This review explores the role of tannin-rich plant fractions in hepatoprotection. The hepatoprotective potential of these compounds is increasingly recognized, particularly through the lens of nanotechnology, which can improve the delivery and absorption of tannin-rich extracts, maximizing their therapeutic potential. Advances in nanocarriers, including nanoparticles, nanoemulsions, and liposomes, have demonstrated improved bioavailability, targeted delivery, and sustained release of tannins, offering a promising avenue for hepatoprotective therapy. Nanotechnology can be engineered to target liver cells specifically, increasing the efficacy of tannin-based treatments while minimizing side effects. Preclinical and clinical insights, regulatory considerations, and future directions for tannin-based nanotherapeutics are discussed, highlighting their potential impact. Studies show that tannin-rich extracts lower serum levels of liver enzymes (ALT, AST) and it is revealed that Tannic Acid can enhance hepatic function at specific additive concentrations and even when injured by Acetaminophen, hepatocytes could revert to their preinjury state after additional Tannic Acid supplementation, and holds clinical potential in the treatment of Acetaminophen induced liver failure, indicating reduced liver damage. While the hepatoprotective properties of tannin-rich plant fractions are promising, challenges remain regarding the standardization and safety of these natural products. Further research is essential to fully understand their mechanisms and optimize their clinical applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.